TY - JOUR AU - Homet Moreno, B. AU - Ribas, A. PY - 2015 DA - 2015// TI - Anti-programmed cell death protein-1/ligand-1 therapy in different cancers JO - Br J Cancer VL - 112 ID - Homet Moreno2015 ER - TY - JOUR AU - Sanmamed, M. F. AU - Chen, L. PY - 2018 DA - 2018// TI - A paradigm shift in cancer immunotherapy: from enhancement to normalization JO - Cell VL - 175 ID - Sanmamed2018 ER - TY - JOUR AU - Brahmer, J. R. AU - Lacchetti, C. AU - Schneider, B. J. AU - Atkins, M. B. AU - Brassil, K. J. AU - Caterino, J. M. AU - Chau, I. AU - Ernstoff, M. S. AU - Gardner, J. M. AU - Ginex, P. PY - 2018 DA - 2018// TI - Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline JO - J Clin Oncol VL - 36 ID - Brahmer2018 ER - TY - JOUR AU - Indini, A. AU - Di Guardo, L. AU - Cimminiello, C. AU - Prisciandaro, M. AU - Randon, G. AU - De Braud, F. AU - Del Vecchio, M. PY - 2019 DA - 2019// TI - Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma JO - J Cancer Res Clin Oncol VL - 145 ID - Indini2019 ER - TY - JOUR AU - Owen, D. H. AU - Wei, L. AU - Bertino, E. M. AU - Edd, T. AU - Villalona-Calero, M. A. AU - He, K. AU - Shields, P. G. AU - Carbone, D. P. AU - Otterson, G. A. PY - 2018 DA - 2018// TI - Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non–small-cell lung cancer JO - Clin Lung Cancer VL - 19 ID - Owen2018 ER - TY - JOUR AU - Okada, N. AU - Kawazoe, H. AU - Takechi, K. AU - Matsudate, Y. AU - Utsunomiya, R. AU - Zamami, Y. AU - Goda, M. AU - Imanishi, M. AU - Chuma, M. AU - Hidaka, N. PY - 2019 DA - 2019// TI - Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study JO - Clin Ther VL - 41 ID - Okada2019 ER - TY - JOUR AU - Verzoni, E. AU - Carteni, G. AU - Cortesi, E. AU - Giannarelli, D. AU - De Giglio, A. AU - Sabbatini, R. AU - Buti, S. AU - Rossetti, S. AU - Cognetti, F. AU - Rastelli, F. PY - 2019 DA - 2019// TI - Real-world efficacy and safety of nivolumab in previously-treated metastatic renal cell carcinoma, and association between immune-related adverse events and survival: the Italian expanded access program JO - Cancer Sci VL - 7 ID - Verzoni2019 ER - TY - JOUR AU - Faje, A. T. AU - Lawrence, D. AU - Flaherty, K. AU - Freedman, C. AU - Fadden, R. AU - Rubin, K. AU - Cohen, J. AU - Sullivan, R. J. PY - 2018 DA - 2018// TI - High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma JO - Cancer VL - 124 ID - Faje2018 ER - TY - JOUR AU - Freeman-Keller, M. AU - Kim, Y. AU - Cronin, H. AU - Richards, A. AU - Gibney, G. AU - Weber, J. S. PY - 2016 DA - 2016// TI - Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes JO - Clin Cancer Res VL - 22 ID - Freeman-Keller2016 ER - TY - JOUR AU - Haratani, K. AU - Hayashi, H. AU - Chiba, Y. AU - Kudo, K. AU - Yonesaka, K. AU - Kato, R. AU - Kaneda, H. AU - Hasegawa, Y. AU - Tanaka, K. AU - Takeda, M. PY - 2018 DA - 2018// TI - Association of immune-related adverse events with nivolumab efficacy in non-small cell lung cancer JO - JAMA Oncol VL - 4 ID - Haratani2018 ER - TY - JOUR AU - Kim, H. I. AU - Kim, M. AU - Lee, S. H. AU - Park, S. Y. AU - Kim, Y. N. AU - Kim, H. AU - Jeon, M. J. AU - Kim, T. Y. AU - Kim, S. W. AU - Kim, W. B. PY - 2017 DA - 2017// TI - Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer JO - Oncoimmunology VL - 7 ID - Kim2017 ER - TY - JOUR AU - Osorio, J. C. AU - Ni, A. AU - Chaft, J. E. AU - Pollina, R. AU - Kasler, M. K. AU - Stephens, D. AU - Rodriguez, C. AU - Cambridge, L. AU - Rizvi, H. AU - Wolchok, J. D. PY - 2017 DA - 2017// TI - Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer JO - Ann Oncol VL - 28 ID - Osorio2017 ER - TY - JOUR AU - Yamauchi, I. PY - 2019 DA - 2019// TI - Incidence, features, and prognosis of immune-related adverse events involving the thyroid gland induced by nivolumab JO - Immunotherapy VL - 14 ID - Yamauchi2019 ER - TY - STD TI - Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer. 2018;20(3):201–7. ID - ref14 ER - TY - JOUR AU - Ricciuti, B. AU - Genova, C. AU - De Giglio, A. AU - Bassanelli, M. AU - Dal Bello, M. G. AU - Metro, G. AU - Brambilla, M. AU - Baglivo, S. AU - Grossi, F. AU - Chiari, R. PY - 2019 DA - 2019// TI - Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis JO - J Cancer Res Clin Oncol VL - 145 ID - Ricciuti2019 ER - TY - STD TI - Lei M, Michael A, Patel S, Wang D. Evaluation of the impact of thyroiditis development in patients receiving immunotherapy with programmed cell death-1 inhibitors. J Oncol Pharm Pract. 2019;25(6):1402–11. ID - ref16 ER - TY - STD TI - Ishihara H, Takagi T, Kondo T, Homma C, Tachibana H, Fukuda H, Yoshida K, Iizuka J, Kobayashi H, Okumi M, et al. Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab. Urol Oncol. 2019;37(6):355.e21–.e29. ID - ref17 ER - TY - STD TI - Toi Y, Sugawara S, Sugisaka J, Ono H, Kawashima Y, Aiba T, Kawana S, Saito R, Aso M, Tsurumi K, et al. Profiling preexisting antibodies in patients treated with anti-PD-1 therapy for advanced non-small cell lung cancer. JAMA Oncol. 2018;5(3):376–83. ID - ref18 ER - TY - STD TI - Cortellini A, Chiari R, Ricciuti B, Metro G, Perrone F, Tiseo M, Bersanelli M, Bordi P, Santini D, Giusti R, et al. Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients. Eurasian J Medicine. 2019;20(4):237–47. ID - ref19 ER - TY - STD TI - Berner F, Bomze D, Diem S, Ali OH, Fassler M, Ring S, Niederer R, Ackermann CJ, Baumgaertner P, Pikor N, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5(7):1043–47. ID - ref20 ER - TY - STD TI - Ahn BC, Pyo KH, Xin CF, Jung D, Shim HS, Lee CY, Park SY, Yoon HI, Hong MH, Cho BC, et al. Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice. J Cancer Res Clin Oncol. 2019;145(6):1613–23. ID - ref21 ER - TY - JOUR AU - Nakamura, Y. AU - Tanaka, R. AU - Asami, Y. AU - Teramoto, Y. AU - Imamura, T. AU - Sato, S. AU - Maruyama, H. AU - Fujisawa, Y. AU - Matsuya, T. AU - Fujimoto, M. PY - 2017 DA - 2017// TI - Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study JO - J Dermatol VL - 44 ID - Nakamura2017 ER - TY - JOUR AU - Judd, J. AU - Zibelman, M. AU - Handorf, E. AU - O'Neill, J. AU - Ramamurthy, C. AU - Bentota, S. AU - Doyle, J. AU - Uzzo, R. G. AU - Bauman, J. AU - Borghaei, H. PY - 2017 DA - 2017// TI - Immune-related adverse events as a biomarker in non-melanoma patients treated with programmed cell death 1 inhibitors JO - Oncologist VL - 22 ID - Judd2017 ER - TY - JOUR AU - Ksienski, D. AU - Wai, E. S. AU - Croteau, N. AU - Fiorino, L. AU - Brooks, E. AU - Poonja, Z. AU - Fenton, D. AU - Geller, G. AU - Glick, D. AU - Lesperance, M. PY - 2019 DA - 2019// TI - Efficacy of nivolumab and pembrolizumab in patients with advanced non–small-cell lung cancer needing treatment interruption because of adverse events: a retrospective multicenter analysis JO - Clin Lung Cancer VL - 20 ID - Ksienski2019 ER - TY - JOUR AU - Rogado, J. AU - Sánchez-Torres, J. M. AU - Romero-Laorden, N. AU - Ballesteros, A. I. AU - Pacheco-Barcia, V. AU - Ramos-Leví, A. AU - Arranz, R. AU - Lorenzo, A. AU - Gullón, P. AU - Donnay, O. PY - 2019 DA - 2019// TI - Immune-related adverse events predict the therapeutic efficacy of anti–PD-1 antibodies in cancer patients JO - Eur J Cancer VL - 109 ID - Rogado2019 ER - TY - JOUR AU - Lesueur, P. AU - Escande, A. AU - Thariat, J. AU - Vauleon, E. AU - Monnet, I. AU - Cortot, A. AU - Lerouge, D. AU - Danhier, S. AU - Do, P. AU - Dubos-Arvis, C. PY - 2018 DA - 2018// TI - Safety of combined PD-1 pathway inhibition and radiation therapy for non-small-cell lung cancer: a multicentric retrospective study from the GFPC JO - Cancer Med VL - 7 ID - Lesueur2018 ER - TY - JOUR AU - Lisberg, A. AU - Tucker, D. A. AU - Goldman, J. W. AU - Wolf, B. AU - Carroll, J. AU - Hardy, A. AU - Morris, K. AU - Linares, P. AU - Adame, C. AU - Spiegel, M. L. PY - 2018 DA - 2018// TI - Treatment-related adverse events predict improved clinical outcome in NSCLC patients on KEYNOTE-001 at a single center JO - Cancer Immunol Res VL - 6 ID - Lisberg2018 ER - TY - STD TI - Bjørnhart B, Hansen KH, Jørgensen TL, Herrstedt J, Schytte T. Efficacy and safety of immune checkpoint inhibitors in a Danish real life non-small cell lung cancer population: a retrospective cohort study. Acta Oncol. 2019;58(7):953–61. ID - ref28 ER - TY - JOUR AU - Lang, N. AU - Dick, J. AU - Slynko, A. AU - Schulz, C. AU - Dimitrakopoulou-Strauss, A. AU - Sachpekidis, C. AU - Enk, A. H. AU - Hassel, J. C. PY - 2019 DA - 2019// TI - Clinical significance of signs of autoimmune colitis in (18)F-fluorodeoxyglucose positron emission tomography-computed tomography of 100 stage-IV melanoma patients JO - Immunotherapy VL - 11 ID - Lang2019 ER - TY - JOUR AU - Fujimoto, D. AU - Yoshioka, H. AU - Kataoka, Y. AU - Morimoto, T. AU - Kim, Y. H. AU - Tomii, K. AU - Ishida, T. AU - Hirabayashi, M. AU - Hara, S. AU - Ishitoko, M. PY - 2018 DA - 2018// TI - Efficacy and safety of nivolumab in previously treated patients with non-small cell lung cancer: a multicenter retrospective cohort study JO - Lung Cancer VL - 119 ID - Fujimoto2018 ER - TY - JOUR AU - Sato, K. AU - Akamatsu, H. AU - Murakami, E. AU - Sasaki, S. AU - Kanai, K. AU - Hayata, A. AU - Tokudome, N. AU - Akamatsu, K. AU - Koh, Y. AU - Ueda, H. PY - 2018 DA - 2018// TI - Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab JO - Lung Cancer VL - 115 ID - Sato2018 ER - TY - JOUR AU - Sanlorenzo, M. AU - Vujic, I. AU - Daud, A. AU - Algazi, A. AU - Gubens, M. AU - Luna, S. A. AU - Lin, K. AU - Quaglino, P. AU - Rappersberger, K. AU - Ortiz-Urda, S. PY - 2015 DA - 2015// TI - Pembrolizumab cutaneous adverse events and their association with disease progression JO - JAMA Dermatol VL - 151 ID - Sanlorenzo2015 ER - TY - JOUR AU - de Moel, E. C. AU - Rozeman, E. A. AU - Kapiteijn, E. H. AU - Verdegaal, E. M. E. AU - Grummels, A. AU - Bakker, J. A. PY - 2019 DA - 2019// TI - Autoantibody development under treatment with immune-checkpoint inhibitors JO - Cancer Immunol Res VL - 7 ID - de Moel2019 ER - TY - JOUR AU - Weber, J. S. AU - Hodi, F. S. AU - Wolchok, J. D. AU - Topalian, S. L. AU - Schadendorf, D. AU - Larkin, J. AU - Sznol, M. AU - Long, G. V. AU - Li, H. AU - Waxman, I. M. PY - 2017 DA - 2017// TI - Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma JO - J Clin Oncol VL - 35 ID - Weber2017 ER - TY - JOUR AU - Horvat, T. Z. AU - Adel, N. G. AU - Momtaz, P. AU - Postow, M. A. AU - Callahan, M. K. AU - Carvajal, R. D. AU - Dickson, M. A. AU - D'Angelo, S. P. AU - Woo, K. M. PY - 2015 DA - 2015// TI - Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial Sloan Kettering cancer center JO - J Clin Oncol VL - 33 ID - Horvat2015 ER - TY - STD TI - Ouwerkerk W, van den Berg M, van der Niet S, Limpens J, Luiten RM. Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review. Melanoma Res. 2019;29(5):453–64. ID - ref36 ER - TY - JOUR AU - Moher, D. AU - Liberati, A. AU - Tetzlaff, J. AU - Altman, D. G. PY - 2009 DA - 2009// TI - Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement JO - BMJ VL - 339 ID - Moher2009 ER - TY - STD TI - The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm. UR - http://www.ohri.ca/programs/clinical_epidemiology/oxford.htm ID - ref38 ER - TY - JOUR AU - Altman, D. G. AU - Bland, J. M. PY - 2011 DA - 2011// TI - How to obtain the confidence interval from a P value JO - BMJ (Clinical research ed) VL - 343 ID - Altman2011 ER - TY - JOUR AU - Tierney, J. F. AU - Stewart, L. A. AU - Ghersi, D. AU - Burdett, S. AU - Sydes, M. R. PY - 2007 DA - 2007// TI - Practical methods for incorporating summary time-to-event data into meta-analysis JO - Trials VL - 8 ID - Tierney2007 ER - TY - JOUR AU - DerSimonian, R. AU - Kacker, R. PY - 2007 DA - 2007// TI - Random-effects model for meta-analysis of clinical trials: an update JO - Contemp Clin Trials VL - 28 ID - DerSimonian2007 ER - TY - JOUR AU - Mantel, N. AU - Haenszel, W. PY - 1959 DA - 1959// TI - Statistical aspects of the analysis of data from retrospective studies of disease JO - J Natl Cancer Inst VL - 22 ID - Mantel1959 ER - TY - JOUR AU - Begg, C. B. AU - Mazumdar, M. PY - 1994 DA - 1994// TI - Operating characteristics of a rank correlation test for publication bias JO - Biometrics VL - 50 ID - Begg1994 ER - TY - JOUR AU - Egger, M. AU - Davey Smith, G. AU - Schneider, M. AU - Minder, C. PY - 1997 DA - 1997// TI - Bias in meta-analysis detected by a simple, graphical test JO - BMJ VL - 315 ID - Egger1997 ER - TY - JOUR AU - Duval, S. AU - Tweedie, R. PY - 2000 DA - 2000// TI - Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis JO - Biometrics VL - 56 ID - Duval2000 ER - TY - JOUR AU - Houghton, A. N. AU - Eisinger, M. AU - Albino, A. P. AU - Cairncross, J. G. AU - Old, L. J. PY - 1982 DA - 1982// TI - Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets JO - J Exp Med VL - 156 ID - Houghton1982 ER - TY - JOUR AU - Cui, J. AU - Bystryn, J. C. PY - 1995 DA - 1995// TI - Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells JO - Arch Dermatol VL - 131 ID - Cui1995 ER - TY - JOUR AU - Laubli, H. AU - Koelzer, V. H. AU - Matter, M. S. AU - Herzig, P. AU - Dolder Schlienger, B. AU - Wiese, M. N. AU - Lardinois, D. AU - Mertz, K. D. AU - Zippelius, A. PY - 2018 DA - 2018// TI - The T cell repertoire in tumors overlaps with pulmonary inflammatory lesions in patients treated with checkpoint inhibitors JO - Oncoimmunology VL - 7 ID - Laubli2018 ER - TY - JOUR AU - Velu, V. AU - Titanji, K. AU - Zhu, B. AU - Husain, S. AU - Pladevega, A. AU - Lai, L. AU - Vanderford, T. H. AU - Chennareddi, L. AU - Silvestri, G. AU - Freeman, G. J. PY - 2009 DA - 2009// TI - Enhancing SIV-specific immunity in vivo by PD-1 blockade JO - Nature VL - 458 ID - Velu2009 ER - TY - JOUR AU - Thibult, M. L. AU - Mamessier, E. AU - Gertner-Dardenne, J. AU - Pastor, S. AU - Just-Landi, S. AU - Xerri, L. AU - Chetaille, B. AU - Olive, D. PY - 2013 DA - 2013// TI - PD-1 is a novel regulator of human B-cell activation JO - Int Immunol VL - 25 ID - Thibult2013 ER - TY - JOUR AU - Le Burel, S. AU - Champiat, S. AU - Mateus, C. AU - Marabelle, A. AU - Michot, J. M. AU - Robert, C. AU - Belkhir, R. AU - Soria, J. C. AU - Laghouati, S. AU - Voisin, A. L. PY - 2017 DA - 2017// TI - Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: a single-centre pharmacovigilance database analysis JO - Eur J Cancer (Oxford, England : 1990) VL - 82 ID - Le Burel2017 ER - TY - JOUR AU - Xu, C. AU - Chen, Y. P. AU - Du, X. J. AU - Liu, J. Q. AU - Huang, C. L. AU - Chen, L. AU - Zhou, G. Q. AU - Li, W. F. AU - Mao, Y. P. AU - Hsu, C. PY - 2018 DA - 2018// TI - Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis JO - BMJ VL - 363 ID - Xu2018 ER - TY - JOUR AU - Wang, D. Y. AU - Salem, J. E. AU - Cohen, J. V. AU - Chandra, S. AU - Menzer, C. AU - Ye, F. AU - Zhao, S. AU - Das, S. AU - Beckermann, K. E. AU - Ha, L. PY - 2018 DA - 2018// TI - Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis JO - JAMA Oncol VL - 4 ID - Wang2018 ER - TY - JOUR AU - Bianchi, M. AU - Meng, C. AU - Ivashkiv, L. B. PY - 2000 DA - 2000// TI - Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids JO - Proc Natl Acad Sci U S A VL - 97 ID - Bianchi2000 ER - TY - JOUR AU - Rogatsky, I. AU - Ivashkiv, L. B. PY - 2006 DA - 2006// TI - Glucocorticoid modulation of cytokine signaling JO - Tissue Antigens VL - 68 ID - Rogatsky2006 ER - TY - STD TI - Hu X, Li WP, Meng C, Ivashkiv LB: Inhibition of IFN-gamma signaling by glucocorticoids. (0022–1767). ID - ref56 ER - TY - JOUR AU - Sachpekidis, C. AU - Larribere, L. AU - Kopp-Schneider, A. AU - Hassel, J. C. AU - Dimitrakopoulou-Strauss, A. PY - 2019 DA - 2019// TI - Can benign lymphoid tissue changes in (18)F-FDG PET/CT predict response to immunotherapy in metastatic melanoma? JO - Cancer Immunol Immunother VL - 68 ID - Sachpekidis2019 ER - TY - JOUR AU - Di Giacomo, A. M. AU - Calabro, L. AU - Danielli, R. AU - Fonsatti, E. AU - Bertocci, E. AU - Pesce, I. AU - Fazio, C. AU - Cutaia, O. AU - Giannarelli, D. AU - Miracco, C. PY - 2013 DA - 2013// TI - Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme JO - Cancer Immunol Immunother VL - 62 ID - Di Giacomo2013 ER - TY - JOUR AU - Teulings, H. E. AU - Limpens, J. AU - Jansen, S. N. AU - Zwinderman, A. H. AU - Reitsma, J. B. AU - Spuls, P. I. AU - Luiten, R. M. PY - 2015 DA - 2015// TI - Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis JO - J Clin Oncol VL - 33 ID - Teulings2015 ER - TY - JOUR AU - Wong, A. N. M. AU - McArthur, G. A. AU - Hofman, M. S. AU - Hicks, R. J. PY - 2017 DA - 2017// TI - The advantages and challenges of using FDG PET/CT for response assessment in melanoma in the era of targeted agents and immunotherapy JO - Eur J Nucl Med Mol Imaging VL - 44 ID - Wong2017 ER - TY - JOUR AU - Sznol, M. AU - Ferrucci, P. F. AU - Hogg, D. AU - Atkins, M. B. AU - Wolter, P. AU - Guidoboni, M. AU - Lebbé, C. AU - Kirkwood, J. M. AU - Schachter, J. AU - Daniels, G. A. PY - 2017 DA - 2017// TI - Pooled analysis safety profile of nivolumab and ipilimumab combination therapy in patients with advanced melanoma JO - J Clin Oncol VL - 35 ID - Sznol2017 ER -